FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder

11May - by Editor - 0 - In STL.News

SILVER SPRING, MD (STL.News) – The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS.  The only other treatment approved for LEMS is only approved for use in adults. “We continue to be committed to facilitating the development and approval of treatments for rare diseases, particularly those in children,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. 

Continue reading FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder at STL.News.

Source link